key: cord-1000202-fvyrv5iv
authors: Smail, Shukur Wasman; Saeed, Muhammad; Twana alkasalias; Khudhur, Zhikal Omar; Younus, Delan Ameen; Rajab, Mustafa Fahmi; Abdulahad, Wayel Habib; Hussain, Hafiz Iftikhar; Niaz, Kamal; Safdar, Muhammad
title: Inflammation, immunity and potential target therapy of SARS-COV-2: a total scale analysis review
date: 2021-02-25
journal: Food Chem Toxicol
DOI: 10.1016/j.fct.2021.112087
sha: 173417343f37c299df8c0fe888cf316b78630e16
doc_id: 1000202
cord_uid: fvyrv5iv

Coronavirus disease-19 (COVID-19) is a complex disease that causes illness ranging from mild to severe respiratory problems. It is caused by a novel coronavirus SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) that is an enveloped positive-sense single-stranded RNA (+ssRNA) virus belongs to coronavirus CoV family. It has a fast-spreading potential worldwide, which leads to high mortality regardless of lows death rates. Now some vaccines or a specific drug are approved but not available for every country for disease prevention and/or treatment. Therefore, it is a high demand to identify the known drugs and test them as a possible therapeutic approach. In this critical situation, one or more of these drugs may represent the only option to treat or reduce the severity of the disease, until some specific drugs or vaccines will be developed and/or approved for everyone in this pandemic. In this updated review, the available repurpose immunotherapeutic treatment strategies are highlighted, elucidating the crosstalk between the immune system and SARS-CoV-2. Despite the reasonable data availability, the effectiveness and safety of these drugs against SARS-CoV-2 needs further studies and validations aiming for a better clinical outcome.

As of January 26, 2021, a sum of 100,346,160 confirmed cases of the COVID-19 have 2 been revealed in 210 nations and territories around the world (1) , that is due to the virus 3 named as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) originated 4 from Wuhan, China in December 2019 (2) . Depending on clinical manifestations, the 5 COVID-19 is grouped into mild, moderate, and severe. In severe cases of COVID-19, the 6 patients exhibit hyper inflammation and cytokine storms (CS) that drive acute lung injury 7 (ALI), acute respiratory distress syndrome (ARDS), disseminated intravascular 8 coagulation (3), multiple organ failure and death (2) . 9 SARS-CoV-2 is a new strain of Coronavirus that's newly capable of infecting humans 10 (4). It is a +ssRNA virus, even though the origin is not yet clear. The source could be 11 from bats as it shares 96% similarity with coronaviruses (CoVs) isolated from bats

The detailed immune response of the virus is not fully understood yet, but it is believed to 1 resemble other CoVs (48). After entering the cell employing endocytosis, the pathogen- Although immune response activates against CoVs infection, the CoVs still can induce 10 infection because they have the mechanism to evade the immune system that may be 11 scrutinized by decrease secretion of IFN-β via expression of the protein by orf3b and orf8 12 (57). Decreasing T lymphocyte by the CoVs is another mechanism of immune evasion 13 which is more common in COVD-19 patients (58). 15 The inflammation which develops during the severe immune response to CoVs like a 16 double-edged sword that can kill the virus, but it also produces CS which culminates by 17 lung damage and death (59) via increasing oxidative stress (60). In patients with COVID-18 19, there is an over-activation of immune responses (61). However, the hyperactive 19 immune inflammation and systemic damage by SARS CoV-2 is yet to be determined. 20 The interaction of the virus with PRR also results in the production of a huge amount of 21 pro-inflammatory cytokines, such as 1L-1β, IL-6, TNF-α (62), and chemokines such as hyper-inflammatory state in severe cases of COVID-19 (59). 2 The inflammatory signature recorded in the blood of COVID 19 patients showed 3 induction in the IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), 4 IFN-γ, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte- Cytokine storm (CS) is the network of molecular events occurring due to excessive and 10 dysregulated immune response to infection (65). It is manifested by excessive 11 accumulation of inflammatory cells, complements, inflammatory cytokines, and 12 chemokines (66). It usually occurs in severe cases of COVID-19 that leads to ARDS and 13 DIC and multiple organ failure. IL-6, TNF-α, and IL-1β play a critical role in driving CS 14 (67). The level of IL-6 is increased in patients infected by SARS-CoV-2, in which it 15 makes a major contribution to tissue damage and inflammation. IL-6 contributes to 16 atherogenesis, it plays a crucial role in the activation of coagulation after the elevation of 17 thrombin-antithrombin III complexes and the prothrombin activation fragment F1 + (68). 18 Moreover, coagulation is induced by IL-6 as a consequence of building hepatic of acute-19 phase proteins comprising of C-reactive protein (CRP), ferritin, and fibrinogen (69). IL-1β also rises in COVID-19 which mediates lung, inflammation of the tissue, fibrosis, 1 and fever (64). 2 TNF is a cell signaling inflammatory cytokine; it acts as an inflammation amplifier in 3 every acute inflammatory situation (70). Blood and tissue samples of COVID-19 patients 4 observed the presence of TNF molecules (71). The expression of adhesion molecules of 5 lung capillary endothelial cells is increased by a pro-inflammatory TNF-α cytokine. 6 Hence, the affinity of the neutrophil to adhere to the capillary endothelial cells is 7 increased (72). The activated neutrophils secrets more chemokines; IL-8 that work with 8 anaphylatoxin (C5a, C4a, and C3a) to provoke neutrophil recruitment to the capillary 9 endothelial cells and then to migrate into the adjacent tissue (73).

The C-C motif ligand 2 (CCL2) is another chemokine released due to fusion of SARS- 11 CoV-2 with ACE2 receptor (74). The CCL2 plays an important role in the migration of 12 monocytes, memory T cells, and basophils and positioning them in tissues to participate 13 in the inflammatory process (75). ARDS is an acute inflammatory lung injury that occurs 14 in severe cases of COVID-19, which is characterized by pulmonary edema, hypoxia and 15 opacification of the lungs upon CT scan (76). It usually develops after one week of the 16 disease in some cases due to elevation of inflammatory cytokines, especially in elderly 17 people (77). Elderly people, those with comorbidities, infected by SARS-CoV-2 tend to 18 be more susceptible to initiate ARDS, which is in line with the death rates detected in 19 older cases when compared with younger individuals (78). Among inflammatory 20 cytokines, VEGF and TNF-α play a central role in driving ARDS (79). In addition, the 21 level of VEGF is elevated in COVID-19 patients. In a study conducted by Kaner et al. 22 (80), they stated that VEGF was overexpressed in the lungs, which can play a vital role in 23 J o u r n a l P r e -p r o o f the increase of pulmonary vascular permeability in the primitive stages of ARDS (80). 1 TNF-α is raised in COVID-19 and it has also a role in pulmonary edema by up-regulating 2 adhesion molecules and disrupting endothelial barrier in the blood vessels (81).

ACE2 is expressed in a wide variety of organs such as lungs, gut, kidney, cardiovascular 4 and central nervous systems, as well as adipose tissues (82). Imai, Kuba (83) described 5 the imperative role of ACE2 in the regulation of innate immunity. They have observed a 6 more serious pulmonary inflammation in mice with deletion mutations of ACE2 7 prompted by acid aspiration compared with wild-type mice. These results can provide a 8 notion that the inflammation could be more severe by the lowered ACE2 expression. The 9 S protein in the SARS-CoV-2 envelope binds to the ACE2 surface protein to induce viral 10 entry into the host cell and the virus also depends on TMPRSS2 as protease to cell entry 11 (32). The latest investigations recognized ACE2 as a doorway "receptor" for the novel 12 SARS-CoV-2 virus, hence, significantly associating inflammation and cardiovascular 13 disorder (84). When SARS-CoV-2 binds to ACE2 receptor, the virus is endocytosed by 14 the host cell and proteolytic cleavage process is activated; thus, the ACE2 losses its 15 protective function (85). The ACE2 system provides a cascade of protection against 16 pulmonary diseases, heart failure and diabetes mellitus (35). 17 Another detrimental effect of SARS-CoV-2 is the dysfunction of endoplasmic reticulum 18 (ER), causing an ER stress response (86). The impaired folding of proteins in the lumen 19 of ER has resulted in the aggregation of misfolded proteins; hence trigger the unfolded 20 protein response (81), which maintains the homeostasis of endoplasmic reticulum 21 organelles (87). Assuming that the ER stress is persisted and it is irreparable, the 22 unfolded protein response (UPR) will trigger the apoptosis process (88). The induction 23 J o u r n a l P r e -p r o o f of ER stress response is activated in case of viral infections. The UPR acts as a defense 1 mechanism against the virus and the protein synthesis is attenuated to minimize the 2 burden on the ER (89). The level of protein entering the ER can fluctuate significantly 3 under various physiological states and natural conditions. At the point when protein 4 production enhances the folding and unfolding of stored proteins in the ER and lead to 5 ER stress. Excessive lipid damage and pro-inflammatory chemokines lead to ER stress. 6 To sustain homeostasis, cells are responsible for defensive signaling pathways known as 7 UPR. UPR signaling pathways activate three vital stress transducers such as PKR-like ER 8 protein kinase (PERK), enacting transcriptional factor-6 (ATF6), or inositol-requiring 9 protein-1 (IRE1). Triggering of these sensors communicates the sign across the ER layer 10 to the cytosol and the nucleus, however lower the function of these can lead to 11 pathogenesis of SARS-CoV-2 (89).

The interaction between CoV and the host, induces the ER stress response and UPR 13 activation. Different signaling processes are modulated through activation of the three 14 branches of UPR; mitogen-activated protein kinase activation, apoptosis, autophagy, and 15 innate immune response (90). Nabirotchkin, Peluffo (91) also reported that ER stress and 16 UPR may participate in the pathogenesis of the novel SARS-CoV-2 virus, and concluded 17 that the utilization of drug repositioning could be a good strategy to treat patients with 6. Immunotherapeutic strategies 20 Here, we focus on promising immunotherapies that increase immunity against SARS-21 CoV-2 or decrease inflammatory cascades since sometimes excessive inflammatory 22 response occurs against the virus that leads to CS syndrome that eventually results in 23 J o u r n a l P r e -p r o o f coagulation abnormalities, as well as, respiratory, and multiple organ failure (92, 93). An 1 immune-modulating therapy also called an anti-inflammatory agent which is used in 2 hyper-inflammatory conditions. Generally, the prediction of healing from CS is 3 unfavorable, hence identification and utilization of such repurpose medication may have 4 a significant effect and probably reduce mortality (57, 94). The application of 5 immunotherapeutic drugs that mostly act as an anti-inflammatory agent is challenging 6 and the side effects of the drugs should be taken into accounts: first, anti-inflammatory 7 agents decrease immunity that delays clearance of the virus and increase the chances of 8 patient to secondary bacterial infection (95). Second, most immunotherapeutic drugs have 9 a single or specific target, as they inhibit only one cytokine, which makes the 10 inflammation difficult to control since inflammation is the result of multiple cytokines 11 (96, 97). Third, some immunotherapeutics are not selective such as JAK inhibitors which 12 may also reduce TNF-α level (98); the latter is very crucial in the removal of viruses (97, 13 99). Last but not the least, some immunotherapeutic should be used in combination with 14 other drugs that counteract their side effects. For instance, corticosteroids increase the 15 chance of bacterial infection by damaging the T lymphocytes (100) therefore, they should 16 be used with antimicrobials; e.g., thymosin (101). The application of anti-inflammatory 17 agents, besides their side effects, could survive the critical case of COVID-19 patients 18 especially one or two weeks after onset of the disease due to CS (97, 102). Therefore, the 19 application of anti-inflammatory agents provides a narrow window for those that their 20 survival window is finite and will probably lead to the achievement of a more positive 21 outcome (97). The safety profile of NSAIDs was not good during SARS-CoV-1 infection because of 6 two opposed actions. First, NSAIDs down-regulate ACE2 in the respiratory system that 7 reduces pulmonary function (104). Second, NSAIDs up-regulate ACE2 especially in 8 diabetic patients and patients that take ACE2 receptor inhibitors (such as losartan) (105), 9 therefore, the over-expression of ACE2 receptors might facilitate the entry of SARS-10 CoV-2 and increases the chance of infection.

Some COVID-19 patients took acetaminophen or ibuprofen to reduce fever and pain, which are 12 the manifestations of the disease. The impact of ibuprofen on human was shown in (Table 1) . 13

Michael Day established that the infected people should not take ibuprofen to reduce fever 14 instead take acetaminophen because that ibuprofen might be an aggravating factor for the disease 15 (106). As of 17 th March, 2020, NHS medical practitioners in the UK announced CAS 16 alert regarding using NSAIDs after worsening the symptoms of four COVID-19 cases as 17 patients were taking these drugs without underlying other health problems (106).

Since May 2019, a review of ibuprofen and ketoprofen has been ongoing with signals 19 that varicella infection and certain bacterial infections could be aggravated by these drugs 20 (107). The Swedish health agency is against using NSAIDs randomly to treat COVID-19 21 symptoms, it explains that the anti-inflammatory and antipyretic effects can mask 22 symptoms of a deterioration in the disease picture in infection (108). A study has shown 23 J o u r n a l P r e -p r o o f that ibuprofen in vitro inhibits peripheral blood mononuclear cells and IgM and IgG 1 synthesis (109). 2 Indomethacin is another NSAID that is used for the treatment of gout and rheumatoid 3 arthritis (110). The in vitro studies verified the efficacy of the drug in inhibiting the 4 replication of the virus and reducing the damage caused by canine CoVs. It is also proven 5 that the in vivo application of indomethacin in an infected dog is effective at a dose of 6 1mg/kg to combat against SARS-CoV-1 (110). 7 The ongoing clinical trials regarding consuming ibuprofen in COVID-19 patients in the 8 UK and Argentina are NCT04334629 and NCT04382768, respectively. While, 9 NCT04383899 is the clinical trial to know the side effects of ibuprofen in patients with 10 COVID-19 among French people. 11 For decades, one of the most important problems in using NSAIDs is the panic that 12 spread in the community due to their side effects including hypertension, renal problems, 13 and gastrointestinal problems (111). Keeping in mind these reasons, there are few 14 completed and ongoing trials concerning the use of NSAIDs in COVID-19 patients. If 15 practitioners and researchers find the lowest safe effective dose of NSAIDs by their study 16 to reduce the symptomatic treatment of COVID-19, it will be a good solution at that 17 moment since there are no drugs and vaccines to overcome the disease. The justifications 18 of not using NSAIDs are not too strong since the upregulation of ACE2 occurs during the 19 chronic use of the drugs which make the person vulnerable to the disease. When the 20 person is infected with the disease, the upregulation of the ACE2 receptor either will not 21 happen strongly during the acute onset of the infection or will not affect the severity of 22 the disease (112). Another justification is that the antipyretic property of the NSAIDs 23 J o u r n a l P r e -p r o o f reduces killing the virus by the body because clinicians believe that fever is the weapon 1 to reduce replication of the virus (113). If this justification is true, it must be fulfilled over 2 other antipyretic agents including acetaminophen. Finally, the evidence of the 3 upregulation of ACE2 by the drug are originated from the animal models, they may not 4 transferable to the human (114). Corticosteroids are potent immunomodulators that suppress the immune system, so they 7 are used to treat various diseases and inflammatory conditions. It is administered at a low 8 dose to treat some cancer and auto-immune diseases in which inflammation is 9 predominated (115). One should be cautious of prescribing corticosteroids for such 10 individuals as they can be like a double-edged sword; this is for several advantages and 11 disadvantages. This group of medication could be used in a CS and the hyper-12 inflammatory state as it could have both an immunosuppressant effect and an anti-13 inflammatory effect (116) (60). The above property could combat CS phenomenon in 14 patients infected with COVID-19, such as ALI, ARDS, and coagulopathy status (3) (57).

The lethal effect of severe COVID-19 pneumonia is related to the pathological 16 inflammatory reaction characterized by the destruction of deep airway and alveoli (117).

Thymosin has been clinically used in patients with COVID-19 in adjunct to 18 corticosteroids to reverse the side effects of corticosteroids (8).

However, some data from China demonstrates that in those patients with severe 20 pneumonia, early introduction of a short course of low dose methylprednisolone could 21 improve both clinical and radiological outcome (118). It has been documented that the 22 J o u r n a l P r e -p r o o f use of dexamethasone as supportive care for moderate and severe COVID-19 patients 1 leads to a decrease in the duration of mechanical ventilator and mortality rate (Table 1) 2 (119-120). The IL-6 production is a response to both infection and tissue injury, which promptly 6 contributes to the host defense via inducing acute phase proteins, hematopoiesis, and 7 inflammation (63). Despite that IL6 expression is controlled by various mechanisms 8 comprising the post-transcriptional and transcriptional process. Often its concentration is 9 debilitating and contributes to multiple autoimmune disorders and inflammatory 10 conditions (127). Based on its position, there are two types of IL-6 receptors (IL-6R): 11 membrane-bound (mIL-6R) and a soluble form (sIL-6R), the latter binds to IL-6 to form 12 a complex which binds to gp130 on the cell membrane to complete the signal 13 transduction system and respond to infection via an inflammatory response (128). 14 Further, the SARS-CoV-2 infection observations found an increase in inflammatory 15 cytokines (129). Hence, the blockage of IL-6 could have a significant impact on reducing 16 inflammation in COVID-19 patients.

Globally, the intensive care beds are limited and with the COVID-19 outbreak, such units 18 will become overwhelmed with severe ARDS cases (130). To date, neither a vaccine nor 19 specific antiviral therapy is available to combat novel CoV, therefore the administration 20 of cytokine inhibitor especially IL-6 which has a role in hyper-inflammation could 21 mitigate the severity of the disease (131) (132). Towards a drug, Tocilizumab (TCZ) is an example of mAb that acts as an IL-6 inhibitor 10 that binds to both mIL-6R and sIL-6R ( Figure 1C ), it is used to treat RA to reduce 11 inflammation. It has been approved to treat cytokine release syndrome followed chimeric showed promised results that the application of this mAb might be beneficial in severe 20 cases of COVID-19 (Table 1) . 21 Lately, many clinical trials have registered to know the efficacy and safety of TCZ to 3 Sarilumab (Kevzara) is also another inhibitor of IL-6 that interferes with IL-6 signaling 4 by binding to both mIL-6R and sIL-6R ( Figure 1C ), it is used for the treatment of RA.

The "NCT04315298" is the identifier for the clinical trial which has been launched in the 6 United States to know the safety profile of Sarilumab in COVID-19 cases. which is a rare disorder characterized by hyper-inflammation (137). Gritti, Raimondi 10 (138) found that siltuximab administration leads to a reduction of both CRPs via 11 inhibition of IL-6 in COVID-19 patients (Table 1) .

IL-6 blockade agents, that act as immune-modulators, besides their advantage for 13 decreasing inflammation in CS of COVID-19, delay viral clearance; this problem can be 14 tackled by combination with antiviral drugs. They also increase vulnerability to a 15 secondary bacterial infection which can be prevented by their administration with 16 antibiotics. It is also important to address the number for scaling severity of disease and 17 determine the number (the time) when these immune-modulatory agents can be applied.

This can be achieved by the measurement of CRP and IL-6 in COVID-19 patients. preventing it to bind with its receptor ( Figure 1C ), consequently the formation of new 11 vasculature and vascular permeability is rendered. Therefore, the application of 12 Bevacizumab may be a favorable medicine for serious and extreme COVID-19 cases.

"NCT04305106" is the clinical trial, titled as, "application of Bevacizumab in severe 14 cases of COVID-19 patients".

"NCT04305106" and "NCT04275414" are the clinical trial titles application of 16 Bevacizumab in severe cases of COVID-19 patients.

All things considered; bevacizumab is important to reduce pulmonary edema that Adalimumab or other anti-TNF for other diseases are less likely to be admitted in 12 hospital.

Altogether, TNF-α inhibitors may improve severe symptoms of COVID-19 because they 14 decrease other potent inflammatory cytokines that are responsible for CS beside TNF-α.

It is better to be given directly after hospitalization before CS begins. Because of its 16 strong anti-inflammatory effects, further clinical trials should be done to assure its safety function, stimulate chemokine production; its products can be up-regulated by the 3 chemokines IP-10, which is found to be significantly increased in severe cases of SARS. 4 The IP-10 levels are extremely high and it seems to be a more reliable marker for viral Emapalumab is humanized mAb with IFN-γ antagonistic property ( Figure 1C ), it is 9 approved in the United States for treatment of primary hemophagocytic 10 lymphohistiocytosis (HLH) if the disease doesn't respond to its primary treatment (152).

It is effective for that disease which is its hyper-inflammation overwhelmed by activation 12 of T cell and macrophage. However, there is no evidence for the contribution of IFN-γ in 13 CS of COVID-19 (153). It is proven that emapalumab decreases CXCL9 which is the 14 chemokine that polarizes T h1 (154). In addition, CXCL9 upregulates RORγt that polarizes 15 toward T h17 (154) which is believed to play a detrimental role in COVID-19 (156). 16 "NCT04324021" is an ongoing clinical trial on using a combination of emapalumab with 17 anakinra to treat CS in COVID-19 patients. Eculizumab (Soliris) and ravulizumab (Ultomiris) are mAbs approved to bind to 10 complement factor C5 and prevent the formation of MAC ( Figure 1C ). They affect the 11 complement system, which may help to minimize organ damage in severe patients. These 12 drugs were first FDA listed for paroxysmal nocturnal hemoglobinuria, which is the rare 13 disease of the blood and later for hemolytic uremic syndrome and myasthenia gravis 14 (159) (160). "NCT04288713" is a clinical trial underpinned the use of eculizumab in 15 SRAS-CoV-2 related CS. 16 Another drug engineered to suppress C5a biological activity is IFX-1 which is also a 17 monoclonal anti-human complement factor C5a antibody designed to inhibit the 18 biological activity of C5a ( Figure 1C ). for complement activation; we must depend on alternative routine indicators that mirror 10 increased complements such as CRP, ferritin, and IL-6. 

The CoVs have strategies to evade the immune system, one of these strategies is to 20 reduce type1 IFNs to dampen the immune system and spread easily from one cell to 21 another (167). lopinavir/ritonavir, remdesivir, and ribavirin could yield better efficacy (Table 1) . 2 The administration of IFN-α2b in five mU twice daily in inhalable form is the guideline the safety of the treatment was reported, however, the sample size included in the study 21 was relatively small (Table 1 ). Yet, there are no specific regulations to collect and use the Figure 1C ). It has been proposed as a potential candidate for COVID-19 10 therapy, taking in to account its relative safety and high affinities. A therapeutic dosage 11 of either 2 mg or 4 mg once daily was enough to achieve inhibition plasma concentration.

The biggest concern about JAK inhibitors, however, is that it can inhibit several (Table 1) . Another mechanism of baricitinib is inhibition of an adaptor protein complex 16 (AP2)-associated protein kinase (AAK) which has the main role in clathrin-mediated 17 endocytosis of the virus. AAK1 inhibitors can block the virus passage into cells and can 18 help to avoid virus infections (190) ( Figure 1C ).

The other major viral input factor is endocytosis. Baricitinib is commercially available is also used for the treatment of irritable bowel disease (199). 4 The detailed mechanism of anti-inflammatory properties are due to its capacity to bind to Jakotinib dihydrochloride monohydrate is also a potent JAK1 and JAK2 inhibitor that is findings of studies on the use of this medication in COVID-19 patients. 11 To sum up, the IL-1 has a critical role in causing ARDS and CS which secondary to 12 SARS-CoV-2 infection, so its inhibition by anakinra may yield a promising result.

However, the safety profile is proven by some researchers but because of the small 14 sample size we cannot guarantee its safety; the conduction of a study with a large sample 15 size is recommended (Table 1) .

On the other hand, methylprednisolone has been widely used during the current 9 COVIDⅠ19 epidemic and the side effect of corticoidⅠinduced death of thymocytes 10 should be considered (216). So, it is suggested to use thymosin α1 before 11 methylprednisolone administration (217).

Yet, no studies have been reported for the uses of thymosin to treat COVID 19, therefore 13 we would like to highlight the importance of investigating its therapeutic action against 14 COVID-19. Cytokines are a group of glycoproteins that control many physiological hemostasis in the 5 body comprising inflammation, hematopoiesis, and tissue remodeling and repair, but 6 those which connect function between two arms of the immune system (non-specific and 7 specific) are the most importance (50). Viral macrophage-inflammatory protein (vMIP), a virus-based protein, is produced by 10 HHV8 as an evading mechanism to protect itself from T cell inflammatory driving 11 killing. Therapeutically, we can get benefit from it to control inflammation because it is a 12 strong chemokine antagonism by inhibiting CXCR4 receptor (242) ( Table 1 ) ( Figure 1C ).

ChiCTR2000029636 is the identifier of a clinical trial that is going to be given in the 14 inhalator form to COVID-19 to know its safety and efficacy. They also uncovered in their study that inflammatory cytokines (IL-6, TNF-α, and IL-1β) 2 and NF-КB would also decrease in tissue culture after 24 and 48 hours of auranofin 3 treatment (Table 1) . 4 Therefore, auranofin will provide "the light at the end of the tunnel" for treatment of ALI 5 and inflammation in COVID-19 patients because it has anti-inflammatory, and antiviral 6 properties. (Table 1) . The authors would like to acknowledge all researchers that have had a significant role in 14 finding any piece of information on this pandemic.

Declaration of interests 16 The author reports no conflicts of interest in this work. Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. 4 Frontiers in Oncology. 2019;9:1186. 

Indomethacin has a potent antiviral activity against SARS coronavirus. Antiviral therapy. CoV-2 is sensitive to type I interferon pretreatment. BioRxiv. 2020. 

Treatment with 1 convalescent plasma for COVIDⅠ19 patients in Wuhan

Convalescent plasma for patients with COVID-19

Treatment of 5 critically ill 6 patients with COVID-19 with convalescent plasma

Covid-19: FDA approves use of convalescent plasma to treat critically 8 ill patients

Use of convalescent 10 plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in

Treatment of COVID-19: old tricks for new 13 challenges

Effect of 15 convalescent plasma therapy on viral shedding and survival in patients with coronavirus 16 disease 2019. The Journal of infectious diseases

The feasibility of convalescent 18 plasma therapy in severe COVID-19 patients: a pilot study

Anti-SARS-CoV-2 virus 20 antibody levels in convalescent plasma of six donors who have recovered from COVID-21 19

Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic 2 hyperinflammation

Ruxolitinib in treatment of 4 severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized 5 controlled trial

Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-8 treated patient with primary myelofibrosis

Imatinib for COVID-19: A case report

Chemokine Receptor 13 Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related 14

Mechanism In Vitro

Pluristem Reports Preliminary Data from its COVID-19 Compassionate

Treating Seven Patients with Acute Respiratory Failure Haifa, Israel

Thalidomide combined with low-21 dose glucocorticoid in the treatment of COVID-19 pneumonia

Opaganib For Patients with Severe COVID-19

Created with BioRender.com The spike protein surrounding SARS-CoV-2 engages in angiotensin-converting enzyme 2 (ACE2) and permits virus entry. Inhibitors like brilacicin (37) and antibodies in the convalescent plasma (15) prevent the binding of the virus to its receptor. TMPRSS2 may help the virus to enter the cell which can be inhibited by RHB-107 (39) therapy. After binding of the virus to its receptor, it enters the endosome. It needs AAK1 for endocytosis as a regulator (it is inhibited Baricitinib (16)). After membrane fusion with the endosomal membrane, it releases naked RNA into the cytosol. Inside the cytoplasm, it translates its RNA-dependent RNA polymerase (RdRp) to replicate its RNA and it undertakes gene expression. After the synthesis of protein and viral RNA, they accumulate inside the ER and Golgi apparatus. they leave ERGIC by exocytosis

The virus releases its genome into the cytosol. Naked RNA is recognized by cytosolic receptors such as RIG-1, MDA-5, or NLRP3. RIG-1 and MDA-5 activate IRFs that enter the nucleus. Once NLRP3 activated by naked RNA, eventually it causes activation of inflammasome which in turn leads to activation of caspase-1 (CA-1), inflammasome is inhibited by tranilast (25) while CA-1 is inhibited by thalidomide (32)

The other transcriptional activations of NF-κB beside inflammatory cytokines and chemokines are ceramidase and phospholipase A2 (PLA2) enzymes. The former catalyzes ceramide in the cell membrane into sphingosine which further catabolized by shingokinase (SK)

Inhibitors like Opaganib (38) can inhibit the SK enzyme, it prevents the formation of S1P that egresses the T lymphocyte from the lymph node to the site of inflammation. Regarding PLA2, it degrades phospholipid (PL) in the cell membrane to form arachidonic acid (AA) that in turn catabolized by cyclo-oxygenase 2 (COX2) enzyme

PLA2 is inhibited by corticosteroids (2) and while and COX2 is inhibited by NSAIDs (1) and auranofin

Interactions of the virus to the cell results in the generation large amount of cytokines (TNF-α, IL-1, IL-6) and chemokines (IL-8 and CXCL2) from the infected cell. The former is inhibited by levamisole (33) to mitigate cytokine storm (CS) and acute lung injury that may occur in COVID-19 patients

The professional antigen-presenting cells, present viral protein to Th cell then different subsets of Th (Th1, Th2, Treg, Th17) is polarized depending on the cytokines. COVID-19 Patients had elevated levels of IL1B, IFN-γ, IP10, and MCP-1 signifying hyper-activation of Th1 cell reactions

IFN-γ causes activation of macrophage through binding to its receptor on it; tyrosine kinase (TYK) is the signal transduction of IFNR

Macrophage activation can be inhibited by prevent binding IFN-γ to its receptor by emapalumab (9) or blocking TYK via imatinib

primarily help B cells to produce antibodies which in turn trigger classical activation of complement 3 (C3) and (C5) which culminate in membrane attack complex (MAC) formation and damage of the viral infected cell. C3 is inhibited by AMY-101 (42). C5 and MAC are inhibited by eculizumab (11) and ravulizumab (12). C3a, C4a, and C5a are also formed which act as anaphylatoxin that attracts neutrophil and macrophage to the site of inflammation and increases oxidative stress that induces acute lung damage (ALI). The oxidative stress is mitigated by the administration of pirfenidone (23) and tranilast (25) and also by the administration of C5a antagonists such as IFX-1 (41). Neutrophil and Monocyte (macrophage) are synthesized and attracted to the site of inflammation by GM-CSF which is augmented by GM-CSF (27)

Th17 cells are associated with driving harmful inflammation in the case J o u r n a l P r e -p r o o f of SARS-CoV-2 infection. The IL-17 is released by Th17 acting as a chemotactic protein that drives monocyte and neutrophil to the site of infection

Both of them are influenced by IL-2 which secretes by naïve T helper cell (Th0) which in turn augmented by T-cell immunotherapy (30). CTL and NK cells are boosted by the administration of IL-2 (26) therapy. Once the SARS-CoV-2 virus is introduced into the tissue cells, such as respiratory epithelial cells

that secrete by activated DCs and viral infected cells, have an essential role in acute phase response and cytokine storm (CS) during SARS-CoV-2 infection. They affect on brain stem to produce fever. They induce the liver to produce acute phase reactants (CRP, ferritin, and fibrinogen). The latter two contribute to coagulopathy and septic shock

TNF-α besides its role in the acute-phase response can bind to its receptor on the blood vessel to increase adhesion molecules and enhances the extravasation of neutrophil that causes ALI. It also works with VEGF to induce pulmonary edema by disrupting the endothelial barrier of lung blood vessels. TNF-α and VEGF are inhibited by preventing binding to their receptor by adalimumab (8) and bevacizumab (7), respectively. Regarding IL-1

Lymphocyte exhaustion and lymphopenia are common in SARS-CoV-2 infection which can be reversed by the administration of programmed cell death-protein1 (PD1/PD-L1) inhibitors nivolumab (13), or cytotoxic T-cell-associated protein 4 (CTLA4) inhibitors BP1-002 (36) could have an important role in the prevention of lymphopenia or restore lymphocyte counts in severe cases of COVID

It decreased the level of CRP (nonsignificantly) but it increased the level of lymphocytes.(338)

Trypsin-like serine protease (S1 family) inhibitor Auranofin Inhibits phosphorylation of JAK-1 and STAT-3, and inhibits COX Inflammatory cytokines (IL-6, TNF-α and IL-1β) and NF-КB would also decreased in tissue culture after 24 and 48 hours of auranofin treatment. It is very effective in decrease viral load of SARS-CoV-2 in Huh7 tissue culture cell by 70% after 24 hours of auranofin treatment and 85% after 48 auranofin